AbbVie unveiled 20 new scientific presentations at the 2026 United European Gastroenterology Week, highlighting long-term and real-world data for its inflammatory bowel disease (IBD) treatments SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The data show sustained clinical and endoscopic improvements in patients with moderate to severe Crohn's disease and ulcerative colitis over periods up to four years. Additionally, AbbVie presented early results on ABBV-466, a novel dual-targeting therapy for Crohn's disease. These findings support AbbVie's leadership in IBD research and may influence future treatment approaches for chronic IBD patients.
AbbVie Inc holds a substantial market cap of $500.80 billion, reflecting its significant presence in the health sector. As of Oct 17, 2026, 13:11 WIB, AbbVie's stock price on Pluang is USD 285.42, showing a 1.34% increase in the last day. The company also offers a dividend yield of 2.44%, with a typical hold time of 93 days among Pluang investors. This market context highlights the strong investor interest as AbbVie advances its research in inflammatory bowel disease treatments.
Eli Lilly trades at a premium 24x forward earnings but shows revenue growth of 47.7% year-over-year, far surpassing major pharma peers like Novo Nordisk and AbbVie. The company raised its 2026 revenue guidance twice, aiming for $85B-$87B, driven by s...
AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance...
